MedTrace Logo

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

NCT07613307 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2026-05-29

No results posted yet for this study

Summary

The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.

Conditions

  • Diabetes Mellitus, Type 2
  • Diabetes Melletus
  • Glucose Metabolism Disorders
  • Metabolic Disorders
  • Nutritional and Metabolic Diseases
  • Endocrine System Diseases
  • Feeding Behavior
  • Behavior
  • Fasting
  • Glucagon-Like Peptide-1 Receptor
  • Glucagon-Like Peptide Receptors
  • Receptors, G-Protein-Coupled
  • Receptors, Cell Surface
  • Membrane Proteins
  • Proteins
  • Receptors, Peptide

Interventions

DRUG

Orforglipron

Administered orally

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • India
  • Saudi Arabia
  • South Africa
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07613307 on ClinicalTrials.gov